Skip to search formSkip to main contentSkip to account menu

Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001

Known as: AMR-001 
A cell-based product containing autologous bone marrow derived CD34 positive and C-X-C chemokine receptor type 4 (CXCR4) positive stem cells with… 
National Institutes of Health

Related topics

Related topics

4 relations
Antigen SensitizationCytotoxic T-LymphocytesT-Cell Activationimmunopotentiation

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Abstract 11330: Predictors of Response to Intracoronary Delivery of CD34+CXCR4+ Enriched Bone Marrow Derived Stem Cells (AMR-001) Early After STEMI
Background. High dose CD34+/CXCR4+ stem cells improve myocardial perfusion when administered via the infarct related artery early… 
2008
2008
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2007
2007
Bone Marrow Derived CD34+CXCR4+ Cells Maintain Viability, Mobility and Sterility up to 72 Hours and Are Compatible with Balloon Dilatation Catheters Used for Intra Coronary Artery Infusion; Pre…
Background: Approximately 20% of patients suffering a ST segment elevated acute myocardial infarction (AMI) have progressive peri… 
2007
2007
CD34+CXCR4+ Cell Therapy (AMR-001) for Myocardial Infarction: Preliminary Processing and Product Results of a Phase I Dose Escalation Study.
Background: Approximately 20% of patients suffering a ST segment elevated acute myocardial infarction (AMI) have progressive peri… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)